Dialysis Prescription
Dialysis Prescription
Lowering the dialysis calcium concentration ( e.g. from 1.25 to 1.0 mmol/L) in this patient may have the effect of providing a stimulus to PTH formation and release.
Phosphate and Calcium Management
Phosphate and Calcium Management
Dietary phosphate control, and adherence to prescribed dose of binder is successful.
Phosphate Binders
Therapeutic avenues include;
- Manipulate dose of calcium-based phosphate binder
- No change or increase in calcium-based binder (if already prescribed vitamin D analogues), depending on serum calcium
- Stop aluminum-based binders if prescribed, and check serum aluminum levels. Aluminum intoxication includes toxic effects on PTH secretion
PTH Management
PTH Management
Vitamin D Sterols
Active 1-hydroxylated vitamin D sterols (calcitriol, 1-alpha) cause direct suppression of PTH. Therapeutic avenues are based on lowering the effective dose;
- Consider discontinuation of vitamin D analogue
- Switch from daily to alternate day, (night-time) oral dosing.
- Switch to intravenous dosing on dialysis 3- or 2- times weekly
Calcimimetics
Over suppression of parathyroid glands with a calcimimetic is possible; hypocalcemia with normal Pi control is consistent with this diagnosis
- Modify calcium-based phosphate binder, and vitamin D dose first.
- Reduce the dose of calcimimetic to maintain serum intact PTH levels between 10-50 pmol/L
Guideline suggestions include;
CSN
7. Vitamin D sterols can be used in the treatment of secondary hyperparathyroidism, but should be discontinued when PTH levels decrease below target levels, or if calcium or phosphate levels increase above target levels.
(Grade C)
KDIGO
4.2.4.f) We suggest that, if the intact PTH levels fall below two times the upper limit of normal for the assay, calcitriol, vitamin D analogs, and/or calcimimetics be reduced or stopped (2C).
